Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
- 10 June 2025
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (7) , 3782-3792
Abstract
This work presents the solid-state evaluation of a new polymorph (Form M) discovered during the early-stage pharmaceutical development of a new chemical entity GDC-6599. Form screening and active pharmaceutical ingredient (API) crystallization development identified Form A of GDC-6599 as the experimentally most stable polymorph, although more stable polymorphs were predicted by crystal structure prediction (CSP). Later, a new polymorph, Form M, was discovered in the crystallization of a kilogram-scale API batch. The powder X-ray diffraction (PXRD) pattern of Form M was consistent with the calculated pattern of the predicted most stable polymorph (Rank 1) by CSP. Form A and Form M were subsequently speculated as enantiotropic polymorphs according to their melting temperatures and enthalpies. Slurry competition (SC) experimentally confirmed Form M as the more stable polymorph at temperatures relevant to pharmaceutical development. To support API manufacturing, a quantitative PXRD method was successfully developed for controlling the Form A percentage during the API crystallization process. To understand the impact of Form M on the drug product performance, pharmaceutical and biopharmaceutical evaluations were carried out. The intrinsic solubility of Form M was found to be 56% of the intrinsic solubility of Form A, consistent with their calculated solubility ratio based on the Gibbs free energy difference predicted by CSP. Biopharmaceutical assessment further suggested that the observed solubility reduction would not impact the biopharmaceutical performance of GDC-6599 at doses relevant for the proposed clinical studies, providing form selection flexibility for clinical formulation development. Accordingly, Form M was recommended for future API manufacturing and solid dosage form development. Meanwhile, Form A was confirmed to be physically stable in a suspension formulation for extemporaneous preparation and was recommended to support the early cohorts of Phase I clinical studies.Keywords
This publication has 41 references indexed in Scilit:
- Formulating Weakly Basic HCl Salts: Relative Ability of Common Excipients to Induce Disproportionation and the Unique Deleterious Effects of Magnesium StearatePharmaceutical Research, 2013
- Stable-Form Screening: Overcoming Trace Impurities That Inhibit Solution-Mediated Phase Transformation to the Stable Polymorph of SulfamerazineJournal of Pharmaceutical Sciences, 2008
- A Major Advance in Crystal Structure PredictionAngewandte Chemie International Edition, 2008
- An Improved Broadband Decoupling Sequence for Liquid Crystals and SolidsJournal of Magnetic Resonance, 2000
- Inferring thermodynamic stability relationship of polymorphs from melting dataJournal of Pharmaceutical Sciences, 1995
- Ramped-Amplitude Cross Polarization in Magic-Angle-Spinning NMRJournal of Magnetic Resonance, Series A, 1994
- Heat of Fusion Measurement of a Low Melting Polymorph of Carbamazepine That Undergoes Multiple-Phase Changes During Differential Scanning Calorimetry AnalysisJournal of Pharmaceutical Sciences, 1991
- Total suppression of sidebands in CPMAS C-13 NMRJournal of Magnetic Resonance (1969), 1982
- On the polymorphism of pharmaceuticals and other molecular crystals. IIMicrochimica Acta, 1979
- On the polymorphism of pharmaceuticals and other molecular crystals. IMicrochimica Acta, 1979